Introduction
Molecular biological studies have now clearly established two major types of glutamate receptors in the central nervous system. Ionotropic glutamate receptors exist as heteromeric complexes composed of subunit proteins that form an integral ligand-gated ion channel [ 1, 21. In contrast, metabotropic glutamate receptors (mGluRs) are G-protein-linked to changes in second messenger formation and modulation of ion channel function [ 3, 41 . This article discusses the biochemical pharmacology of in situ and cloned mGluRs, and the functional consequences of their activation. mGluR molecular structure Rat mGluRs have been cloned recently [5, 61 and, like other G-protein-coupled receptors, found to possess seven hydrophobic transmembrane regions. However, mGluRs are structurally unique, having no sequence homology with other known G-protein-linked receptors. A family of mGluRs has now been described [7, 81 (see Table l ), and the transduction mechanisms for members of this family have been demonstrated following expression in Xenopus oocytes or stably transfected nonneuronal cells. When compared with other G-protein-coupled receptors, mGluRs are large in size (872-1199 amino acids) with as many as 570 amino acids in the extracellular domain prior to the first transmembrane region. The difference in size between members of the mGluR family mostly reflects a truncated intracellular region near the C-terminal amino acid. The site at which glutamate binds to mGluRs, the structural region which interAbbreviations used: ACPD, 1-aminocyclopentane-1,3-dicarboxylic acid; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate; L-AP3, L-2-amino-3-phosphonopropionic acid; CHO, Chinese hamster ovary; LTP, long-term potentiation; mGluR, metabotropic glutamate receptor; NMDA, N-methyh-aspartate. acts with G-protein complexes, and the in situ transduction pathways for some mGluRs, remain to be established. Furthermore, additional members of this receptor family may be discovered in the future.
mGluR coupling to phosphoinositide hydrolysis
The mGluRs were initially described by the effects of non-selective agonists such as L-glutamate, quisqualate [an a-amino-3-hydroxy-5-methyl-4-iso- Table 2 ).
Consistent with this, ( k )trans-ACPD induces calcium-mediated chloride currents in Xenopus oocytes injected with rat brain mRNA [18] . In rat hippocampal slices, the order of agonist potency for stimulation of phosphoinositide hydrolysis is quisqualate > ( f )trans-ACPD 2 ibotenate > ( k )cis- 
ACPD AMPA (see Figure 1 and (Table 2) . When compared with lS,3R-ACPD, 1R,3S-ACPD is a weak partial agonist with less selectivity (Table 2) . Thus, the observation of functional effects produced by 1S,3R-ACPD, which are not potently mimicked by 1R,3S-ACPD, is a useful criterium for the involvement of mGluRs. No potent and selective competitive antagonists for phosphoinositide-coupled mGluRs have yet been described. The 1,-aspartate analogue, L-2-amino-3-phosphonopropionic acid (L-AP3) acts as a weak partial agonist at some phosphoinositidelinked mGluRs, and has little affinity for ionotropic glutamate receptors at these concentrations. Thus, it will inhibit activation by more efficacious mGluR agonists, such as lS,3Z?-ACPD, quisqualate and ibotenate, in some tissues such as rat hippocampus and cortex [12, 221. Recent evidence also suggests that i,-AP3 inhibits mGluRs in a long-lasting noncompetitive manner by desensitizing phosphoinositide responses to other mGluR agonists . 
AMPA
The compound 1,-aspartate /3-hydroxamate may also inhibit phosphoinositide-coupled mGluRs by the same non-competitive mechanism [25] . ( f ) Trans-ACPD or its 1 S,3R-ACPD isomer also potently inhibit forskolin-stimulated cyclic AMP formation in situ. lR,3S-ACPD is much less potent than lS,3R-ACPD in producing this effect.
This has been shown in rat hippocampal slices [29] , guinea pig cortical slices [ 301 and striatal neurons in culture [31] . In the rat hippocampus [32] and when
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comparing cloned mGluRs [7, 8, 261, quisqualate is much less potent in inhibiting cyclic AMP formation than it is in stimulating phosphoinositide hydrolysis. Thus, mGluRs that are negatively coupled to cyclic AMP formation differ from phosphoinositide-coupled mGluRs by their relative insensitivity to quisqualate. In membranes prepared from rat forebrain, lS,3R-ACPD-sensitive 'Hglutamate binding sites that are quisqualate-sensitive and insensitive have been found [33] . These binding sites might therefore represent phosphoinositide-linked and negatively coupled cyclic AMP sites, respectively. In the rat hippocampus, 1S,3R-ACPD inhibition of forskolin-stimulated cyclic AMP formation is fully mimicked by L -A P~ [32] , in contrast to the inhibition of 1S,3R-ACPD that was found when measuring phosphoinositide hydrolysis ( f ) Trans-ACPD also increases basal cyclic AMP levels in preparations that include mCluR1-expressing cells [26] and rat hippocampal slices [29, 341 . In the rat hippocampus, 1S,3R-ACPD is a relatively potent agonist in stimulating cyclic AMP, while 1R,3S-ACPD is much less potent [34] . 1 S,3R-ACPD stimulation of cyclic AMP formation is clearly distinguished from the inhibitory effects on forskolin-stimulated cyclic AMP, since it is blocked by L -A P~ [34] . Adenosine deaminase abolishes 1S,3 R-ACPD-stimulated cyclic AMP accumulation in rat hippocampal slices [35] . This suggests that cyclic AMP stimulation by endogenous levels of adenosine is being potentiated by mCluR activation. Other activators of adenylate cyclase, including prostaglandin F,, vasoactiveintestinal polypeptide and isoproterenol, are also potentiated by lS,3R-ACPD. Thus, this mCluR response is probably not due to direct coupling to adenylate cyclase, but similar other G-proteincoupled receptors (i.e. a-adrenergic [36] ) may be related to an mCluR that potentiates other agonists which are directly coupled to G,. It is not known if mCluR1-mediated increases in cyclic AMP formation are also indirectly mediated by this mechanism.
[121.
Functional consequences of mGluR activation
Selective activation of mGluRs by ( k )trans-ACPD has been shown to lead to functional consequences that include increases and decreases in neuronal excitability, alterations in neurotransmitter release, and pathological and behavioural sequelae. post-synaptic potentials [39] and direct depolarization [41] . It has been difficult to correlate these electrophysiological effects to changes in mGluRmediated second messengers [4] , and this may reflect direct mGluR/G-protein modulation of ion channels per se. The clones mGluR3 and mGluR4 do not appear to couple to a known second messenger system [7] , and possibly these clones are directly coupled to ion channels in situ. Recent evidence suggests that phosphoinositide-coupled mGluRs are linked to modulation of ionotropic glutamate receptors. The NMDA receptor is important in plasticity phenomenon that include long-term potentiation (LTP) and epileptogenesis [42] , and can be modulated by its phosphorylation state [43] . NMDA receptor subunit proteins that have been cloned possess consensus sequences for protein kinase C phosphorylation [44] . Activation of hippocampal mCluRs by 1S,3R-ACPD enhances NMDA receptor currents [45] . This effect of 1S,3R-ACPD is mimicked by phorbol esters which directly activate protein kinase C, and can be blocked by the protein kinase C inhibitor, staurosporine [46] . Thus, it appears that mGluR activation of phosphoinositide hydrolysis and subsequent activation of protein kinase C is responsible for positive modulation of the NMDA receptor. This mCluR-mediated increase in NMDA currents may underly the induction of LTP in the hippocampus [47] . Pathological modulation of NMDA receptors by phosphoinositide-coupled mCluRs also occurs. Intrahippocampal injection of 1S,3R-ACPD produces delayed limbic seizures and selective neuronal cell loss which can be prevented by an NMDA receptor antagonist [Zl] . Thus, specific antagonists for the mGluR(s) which modulate NMDA receptors are potential anticonvulsant and neuroprotective agents.
In contrast to the hippocampus (see above), injection of lS,3R-ACPD into the rat striatum leads to increased motor activity that manifests itself as contralateral turning [ 481. This behavioural effect has a pharmacology similar to mGluR-activation of phosphoinositide hydrolysis. For example, 1S,3R-ACPD appears as a full agonist, and 1R,3S-ACPD is a partial agonist which can partially antagonize 1S,3R-ACPD turning [49] . L -A P~ also acts as a partial agonist, including modest turning alone, and partially inhibiting lS,3R-ACPD. 
Introduction
The primary cause(s) of neurodegenerative diseases, including ischaemic and seizure-related brain damages, are far from fully elucidated [I] . Several factors may play important roles in the etiology of these diseases, including free radical formation and, perhaps, autoimmune mechanisms. Studies in recent years have, however, been focused on the role of the central excitatory amino acid (EAA) neurotransmitters, (9-glutamic acid (Glu) and (9-aspartic acid, in processes causing neuron injury and, ultimately, death [2] . The view that hyperactivity of central Glu neurons is an important causative factor in neurodegenerative processes ('excitotoxicity') is supported by in vitro and in vivo studies in model systems [2] .
In the progression of Alzheimer's disease, loss of Glu neurons is also observed [3] . The resulting hypoactivity of central EAA neuronal pathways has recently been proposed to be associated with the learning and memory deficits observed in Alzheimer patients [3, 41. There is some evidence that hypoactivity of central EAA system(s) may also be a factor of importance in schizophrenia [ 51.
Since hyperactivity as well as hypoactivity of EAA neuronal systems may be implicated in Alzheimer's disease, drugs capable of both protecting and activating EAA receptors may be of therapeutic interest. Partial agonists with appropriately balanced agonistlantagonist profiles [6, 71, or compounds capable of enhancing EAA receptor functions, may be of interest in Alzheimer's disease as potential learning-and memory-stimulating drugs. 
Excitatory amino acid receptor subtypes
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